Study of BHV-1400 in IgA Nephropathy

Launched by BIOHAVEN THERAPEUTICS LTD. · Jun 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called BHV-1400 for people with IgA Nephropathy, a kidney condition where a protein called IgA builds up and causes damage. The main goal of this early-stage study is to find out if BHV-1400 is safe and well-tolerated by patients with this condition.

People who might be eligible to join the study are those who have had a kidney biopsy—a small sample of kidney tissue examined by a doctor—that confirms they have IgA Nephropathy. The study is open to adults of all genders, but it has not started recruiting participants yet. It’s important that participants do not have other types of kidney disease or IgA Nephropathy caused by another condition. If you join the trial, the doctors will closely monitor your health to see how your body responds to the treatment and to make sure it does not cause any serious side effects.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Participants must have biopsy-confirmed IgA Nephropathy
• Key Exclusion Criteria:
• • 1. Any secondary IgAN
• • 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause